Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
(See required screening study ALLIANCE A151216)
EA5142 permanently closed to accrual, effective October 1st, 2019.